Tiziana Life Sciences Ltd
$1.21
0%
2026-04-21 09:50:00
www.tizianalifesciences.com
NCM: TLSA
Explore Tiziana Life Sciences Ltd stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$143.81 M
Current Price
$1.21
52W High / Low
$2.6 / $0.87
Stock P/E
—
Book Value
$0.08
Dividend Yield
—
ROCE
-401.27%
ROE
-2.32%
Face Value
—
EPS
$-0.12
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
9
Beta
0.37
Debt / Equity
1.16
Current Ratio
1.72
Quick Ratio
1.02
Forward P/E
-5.94
Price / Sales
—
Enterprise Value
$133.07 M
EV / EBITDA
-7.21
EV / Revenue
—
Rating
None
Target Price
$7.98
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Savara Inc. | $5.61 | — | $1.15 B | — | -52.68% | -63.45% | $7 / $1.89 | $0.8 |
| 2. | Ernexa Therapeutics Inc. | $0.19 | — | $5.87 M | 0.34% | -342.48% | -6.87% | $4.05 / $0.18 | $0.31 |
| 3. | Nuvectis Pharma, Inc. | $8.33 | — | $235.78 M | — | -149.75% | -1.88% | $11.52 / $5.55 | $0.72 |
| 4. | Enlivex Ltd. | $0.88 | — | $207.92 M | — | -0.65% | 1.26% | $2.1 / $0.66 | $8.15 |
| 5. | Entrada Therapeutics, Inc. | $13.56 | — | $535.6 M | — | -44.74% | -39.13% | $14.49 / $4.93 | $8.5 |
| 6. | Lunai Bioworks Inc. | $0.34 | — | $12.33 M | — | 88.63% | -3.66% | $5.5 / $0.15 | $-0.56 |
| 7. | Kairos Pharma, Ltd. | $0.63 | — | $13.1 M | — | -87.87% | -97.99% | $2.11 / $0.4 | $0.37 |
Quarterly Results
Figures shown in M / B
| Sales |
|---|
| Operating Profit |
| Net Profit |
| EPS in Rs |
Profit & Loss
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -15.79 M | -17.98 M | -14.59 M | -27.37 M |
| Net Profit | -11.86 M | -17.69 M | -15.4 M | -23.42 M |
| EPS in Rs | -0.09 | -0.14 | -0.12 | -0.18 |
Balance Sheet
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 11.28 M | 12.18 M | 26.48 M | 48.83 M |
| Total Liabilities | 7.35 M | 6.65 M | 6.91 M | 7.55 M |
| Equity | 3.94 M | 5.54 M | 19.57 M | 41.28 M |
| Current Assets | 7.51 M | 7.34 M | 24.28 M | 48.68 M |
| Current Liabilities | 7.35 M | 6.54 M | 6.66 M | 7.55 M |
Cash Flow
Last available yearly cash flow history
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Operating CF | -1.53 M | -15.7 M | -19.61 M | -21.76 M |
| Investing CF | -0.07 M | -1.25 M | -4 M | 0.13 M |
| Financing CF | 4.5 M | 0.04 M | -0.06 M | -0.02 M |
| Free CF | -1.54 M | -15.7 M | -19.61 M | -21.78 M |
| Capex | -0.02 M | — | — | -0.02 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 32.94% | -14.9% | 34.25% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.